Trial record 3 of 81 for:
Lupus AND (woman OR women OR female)
To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2004 by Genelabs Technologies.
Recruitment status was Active, not recruiting
Information provided by:
First received: January 30, 2003
Last updated: December 26, 2007
Last verified: November 2004
The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).
Drug: Prasterone (GL701)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
||A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Women at least 18 years of age.
- Meet ACR criteria for diagnosis of SLE.
- Concomitant treatment with prednisone at a dose of ≥5 mg/day over the last 30 days prior to Screening visit.
- Cumulative history of oral glucocorticoid use for at least 6 months over the last year prior to the Screening Visit (the 6 months do not have to be consecutive).
- Patient has lumbar spine and proximal femur anatomy suitable for measurement by DXA with at least 3 evaluable vertebrae from L1 to L4.
- SLEDAI ≥3 at the Qualifying Visit.
- Women of child-bearing potential must have a negative serum pregnancy test (at the Screening Visit) and agree to use a reliable form of birth control while participating in the study.
- Patient is fully ambulatory.
- Patient has read and signed an Informed Consent Form.
- History of breast cancer or malignancy of the reproductive tract organs.
- History of any other cancers unless no evidence of disease for 5 years.
- History of endometrial hyperplasia.
- End stage renal disease or receiving hemodialysis treatment.
- Any disease or condition that would preclude the accurate measurement of bone mineral density of the lumbar spine or proximal femur by dual X-ray absorptiometry.
- A T-score of less than or equal to - 2.5 of the L-spine or proximal femur at Screening DXA assessment.
- Unstable cardiac disease.
- Conditions causing bone loss such as hyperparathyroidism, Cushing's disease, thyrotoxicosis, chronic diarrheal state or malabsorption, renal tubular acidosis, or anorexia nervosa.
- Significant hepatic disease (i.e., cirrhosis).
- Body mass index > 35 kg/m2 or weight >300 lbs.
- Patients who are pregnant or breast feeding.
- Patients who require glucocorticoids by an alternate day dosing schedule.
- Known hypersensitivity to DHEA, or the inactive ingredients used in the GL701 formulation (cornstarch, lactose, magnesium stearate).
- Known medical contraindication or hypersensitivity to Calcium/Vitamin D.
- Participation in any prior DHEA or GL701 study.
- Use of investigational agents within 30 days of the Screening Visit or 10 half-lives of the agent.
- Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease).
- The patient is taking or has taken one of the medications listed below:
- Use of calcitonin within 30 days prior to Screening Visit.
- Fluorides > 1 mg/day at any time prior to the study.
- Strontium at pharmacologic dose at any time.
BISPHOSPHONATE USE as follows:
- Any use within 90 days prior to the Screening Visit.
- ≥ 2 weeks of use in the last year prior to the Screening Visit.
- ≥ 3 months of use in the last 2 years prior to the Screening Visit.
- ≥ 1 intravenous dose over the last 2 years prior to the Screening Visit.
- ≥ 6 months of life-time exposure prior to the Screening Visit.
ESTROGENIC STEROIDS (Except for oral contraceptives):
- Estrogenic steroids (HRT) within 60 days of the Screening Visit.
- Selective estrogen receptor modulator (raloxifene) within 60 days of the Screening Visit.
- Parathyroid hormone (PTH) within six months of the Screening Visit.
- Use of any androgens, including prescription or nutritional supplement DHEA, within 30 days of the Screening Visit.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00053560
No publications provided by Genelabs Technologies
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008 Aug;35(8):1567-75. Epub 2008 Jul 15.
||Kenneth E. Schwartz, MD/Vice President, Medical Affairs, Genelabs Technologies, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 30, 2003
||December 26, 2007
||United States: Food and Drug Administration
Keywords provided by Genelabs Technologies:
systemic lupus erythematosus
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 05, 2013
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Immune System Diseases
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists